Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent

Brain Research

Volumn 843, Issue 1-2, 1999, Pages 87-94

  Beffert, Uwe ^a,b   Cohn, Jeffrey S ^c   Petit Turcotte, Caroline ^a,b   Tremblay, Michel ^c   Aumont, Nicole ^b   Ramassamy, Charles ^b   Davignon, Jean ^c   Poirier, Judes ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Amyloid; Alzheimer's disease; Apolipoprotein E

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRONTAL CORTEX; GENOTYPE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; CEREBELLUM; FEMALE; FRONTAL LOBE; GENOTYPE; HIPPOCAMPUS; HUMANS; MALE; REFERENCE VALUES;

EID: 0032829336     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01894-6     Document Type: Article

References (50)

1. Aleshkov S., Abraham C.R., Zannis V.I. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide β (1-40). Relevance to Alzheimer's disease. Biochemistry. 36:1997;10571-10580.
2. Beffert U., Arguin C., Poirier J. The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimer's disease. Neurosci. Lett. 259:1999;29-32.
3. Beffert U., Aumont N., Dea D., Lussier-Cacan S., Davignon J., Poirier J. β-amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons. J. Neurochem. 70:1998;1458-1466.
4. Beffert U., Aumont N., Dea D., Lussier-Cacan S., Davignon J., Poirier J. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Mol. Brain Res. 68:1999;181-185.
5. Beffert U., Poirier J. ApoE associated with lipid has a reduced capacity to inhibit β-amyloid fibril formation. NeuroReport. 9:1998;3321-3323.
6. Bellosta S., Nathan B.P., Orth M., Dong L.M., Mahley R.W., Pitas R.E. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J. Biol. Chem. 270:1995;27063-27071.
7. Bertrand P., Poirier J., Oda T., Finch C.E., Pasinetti G.M. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer's disease. Mol. Brain Res. 33:1995;174-178.
8. Cohn J.S., Tremblay M., Amiot M., Bouthillier D., Roy M., Genest J., Davignon J. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler., Thromb., Vasc. Biol. 16:1996;149-1597.
9. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
10. DeMattos R.B., Curtiss L.K., Williams D.L. A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins. J. Biol. Chem. 273:1998;4206-4212.
11. M.R. Emmerling, S. Gracon, A.E. Roher, Towards a unifying hypothesis of Alzheimer's disease pathogenesis and pathophysiology, in: S. Gauthier (Ed.), Clinical Diagnosis and Management of Alzheimer's disease, Martin Dunitz, London, UK, 1999, pp. 33-53.
12. Evans K.C., Berger E.P., Cho C.G., Weisgraber K.H., Lansbury P.T. Jr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 92:1995;763-767.
13. Fagan A.M., Bu G., Sun Y., Daugherty A., Holtzman D.M. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J. Biol. Chem. 271:1996;30121-30125.
14. Fredenrich A., Giroux L.M., Tremblay M., Krimbou L., Davignon J., Cohn J.S. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions. J. Lipid Res. 38:1997;1421-1432.
15. Gearing M., Mori H., Mirra S.S. Aβ-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann. Neurol. 39:1996;395-399.
16. Harr S.D., Uint L., Hollister R., Hyman B.T., Mendez A.J. Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. J. Neurochem. 66:1996;2429-2435.
17. Holtzman D.M., Pitas R.E., Kilbridge J., Nathan B., Mahley R.W., Bu G.J., Schwartz A.L. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived cell line. Proc. Natl. Acad. Sci. U. S. A. 92:1995;9480-9484.
18. Ishii K., Tamaoka A., Mizusawa H., Shoji S., Ohtake T., Fraser P.E., Takahashi H., Tsuji S., Gearing M., Mizutani T., Yamada S., Kato M., St. George-Hyslop P.H., Mirra S.S., Mori H. Aβ-1-40 but not Aβ-1-42 levels in cortex correlate with apolipoprotein E ε4 allele dosage in sporadic Alzheimer's disease. Brain Res. 748:1997;250-252.
19. Jarrett J.T., Lansbury P.T. Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 73:1993;1055-1058.
20. 42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 94:1997;1550-1555.
21. Khachaturian Z.S. Diagnosis of Alzheimer's disease. Arch. Neurol. 42:1985;1097-1105.
22. Kim K.S., Wen G.Y., Bancher C., Chen C.M.J., Sapienza V.J., Hong H., Wisniewski H.M. Detection and quantitation of amyloid β-peptide with 2 monoclonal antibodies. Neurosci. Res. Commun. 7:1990;113-122.
23. LaDu M.J., Falduto M.T., Manelli A.M., Reardon C.A., Getz G.S., Frail D.E. Isoform-specific binding of apolipoprotein E to β-amyloid. J. Biol. Chem. 269:1994;23403-23406.
24. LaDu M.J., Lukens J.R., Reardon C.A., Getz G.S. Association of human, rat, and rabbit apolipoprotein E with β-amyloid. J. Neurosci. Res. 49:1997;9-18.
25. LaDu M.J., Pederson T.M., Frail D.E., Reardon C.A., Getz G.S., Falduto M.T. Purification of apolipoprotein E attenuates isoform-specific binding to β-amyloid. J. Biol. Chem. 270:1995;9039-9042.
26. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
27. Lambert J.C., Berr C., Pasquier F., Delacourte A., Frigard B., Cottel D., Pérez-Tur J., Mouroux V., Mohr M., Cecyre D., Galasko D., Lendon C., Poirier J., Hardy J., Mann D., Amouyel P., Chartier-Harlin M.C. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Hum. Mol. Genet. 7:1998;1511-1516.
28. Linton M.F., Gish R., Hubl S.T., Butler E., Esquivel C., Bry W.I., Boyles J.K., Wardell M.R., Young S.G. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 88:1991;270-281.
29. Mann D.M.A., Iwatsubo T., Pickering-Brown S.M., Owen F., Saido T.C., Perry R.H. Preferential deposition of amyloid β protein (Aβ) in the form Aβ(40) in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Neurosci. Lett. 221:1997;81-84.
30. Nalbantoglu J., Gilfix B.M., Bertrand P., Robitaille Y., Gauthier S., Rosenblatt D.S., Poirier J. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. Ann. Neurol. 36:1994;889-895.
31. Nathan B.P., Bellosta S., Sanan D.A., Weisgraber K.H., Mahley R.W., Pitas R.E. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 264:1994;850-852.
32. Nathan B.P., Chang K.C., Bellosta S., Brisch E., Ge N.F., Mahley R.W., Pitas R.E. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J. Biol. Chem. 270:1995;19791-19799.
33. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 342:1993;697-699.
34. Puttfarcken P.S., Manelli A.M., Falduto M.T., Getz G.S., LaDu M.J. Effect of apolipoprotein E on neurite outgrowth and β-amyloid-induced toxicity in developing rat primary hippocampal cultures. J. Neurochem. 68:1997;760-769.
35. Raby C.A., Morganti-Kossmann M.C., Kossmann T., Stahel P.F., Watson M.D., Evans L.M., Mehta P.D., Spiegel K., Kuo Y.M., Roher A.E., Emmerling M.R. Traumatic brain injury increases β-amyloid peptide 1-42 in cerebrospinal fluid. J. Neurochem. 71:1998;2505-2509.
36. Rall S.C. Jr., Weisgraber K.H., Mahley R.W., Human apolipoprotein E. The complete amino acid sequence. J. Biol. Chem. 257:1982;4171-4178.
37. Rebeck G.W., Reiter J.S., Strickland D.K., Hyman B.T. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 11:1993;575-580.
38. Scacchi R., Gambina G., Ruggeri M., Martini M.C., Ferrari G., Silvestri M., Schiavon R., Corbo R.M. Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. Neurosci. Lett. 259:1999;33-36.
39. Slooter A.J.C., de Knijff P., Hofman A., Cruts M., Breteler M.M.B., Van Broeckhoven C., Havekes L.M., van Duijn C.M. Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci. Lett. 248:1998;21-24.
40. Strittmatter W.J., Saunders A.M., Schmechel D.E., Pericak-Vance M.A., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90:1993;1977-1981.
41. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M.A., Schmechel D.E., Saunders A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8098-8102.
42. Sun Y.L., Wu S., Bu G.J., Onifade M.K., Patel S.N., LaDu M.J., Fagan A.M., Holtzman D.M. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J. Neurosci. 18:1998;3261-3272.
43. Urmoneit B., Prikulis I., Wihl G., D'Urso D., Frank R., Heeren J., Beisiegel U., Prior R. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab. Invest. 77:1997;157-166.
44. Utermann G., Langenbeck U., Beisiegel U., Weber W. Genetics of the apolipoprotein E system in man. Am. J. Hum. Genet. 32:1980;339-347.
45. Weisgraber K.H., Rall S.C. Jr., Mahley R.W. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J. Biol. Chem. 256:1981;9077-9083.
46. Wood S.J., Chan W., Wetzel R. Seeding of Aβ fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry. 35:1996;12623-12628.
47. Yang D.S., Small D.H., Seydel U., Smith J.D., Hallmayer J., Gandy S.E., Martins R.N. Apolipoprotein E promotes the binding and uptake of β-amyloid into Chinese hamster ovary cells in an isoform-specific manner. Neuroscience. 90:1999;1217-1226.
48. Yang D.S., Smith J.D., Zhou Z., Gandy S.E., Martins R.N. Characterization of the binding of amyloid-β peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J. Neurochem. 68:1997;721-725.
49. Zannis V.I., Just P.W., Breslow J.L. Human apolipoprotein E isoprotein subclasses are genetically determined. Am. J. Hum. Genet. 33:1981;11-24.
50. Zhou Z., Smith J.D., Greengard P., Gandy S.E. Alzheimer amyloid-β peptide forms denaturant-resistant complex with type ε3 but not type ε4 isoform of native apolipoprotein E. Mol. Med. 2:1996;175-180.